Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura

British Journal of Haematology

Volumn 151, Issue 5, 2010, Pages 488-494

  Lotta, Luca A ^a,b   Mariani, Mariagabriella ^a,b   Consonni, Dario ^b,c   Mancini, Ilaria ^a,b   Palla, Roberta ^a,b   Maino, Alberto ^a,b   Vucelic, Dragica ^d   Pizzuti, Michele ^e   Mannucci, Pier M ^a,b   Peyvandi, Flora ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Unit of Epidemiology   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e SAN CARLO HOSPITAL   (Italy)

Author keywords

ADAMTS13; Recurrence; Relapse; Thrombotic thrombocytopenic purpura

Indexed keywords

CLOPIDOGREL; HEMOGLOBIN; LACTATE DEHYDROGENASE; TICLOPIDINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PLATELET COUNT; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REGISTRIES;

EID: 78349279947     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08385.x     Document Type: Article

References (15)

1. Amorosi, E.L. & Ultmann, J.E. (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine, 45, 139-159.
2. Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L. & Palevsky, P.; Acute Dialysis Quality Initiative workgroup. (2004) Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care, 8, R204-R212.
3. Böhm, M., Betz, C., Miesbach, W., Krause, M., Von Auer, C., Geiger, H. & Scharrer, I. (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. British Journal of Haematology, 129, 644-652.
4. Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.L., Vanhille, P., Vernant, J.P., Meyer, D. & Veyradier, A. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood, 109, 2815-2822.
5. Jin, M., Casper, T.C., Cataland, S.R., Kennedy, M.S., Lin, S., Li, Y.J. & Wu, H.M. (2008) Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. British Journal of Haematology, 141, 651-658.
6. Kremer Hovinga, J.A., Vesely, S.K., Terrell, D.R., Lammle, B. & George, J.N. (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 115, 1500-1511.
7. Moake, J.L. (2002) Thrombotic microangiopathies. New England Journal of Medicine, 347, 589-600.
8. Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. & Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 127, 433-439.
9. Peyvandi, F., Lavoretano, S., Palla, R., Feys, H.B., Vanhoorelbeke, K., Battaglioli, T., Valsecchi, C., Canciani, M.T., Fabris, F., Zver, S., Réti, M., Mikovic, D., Karimi, M., Giuffrida, G., Laurenti, L. & Mannucci, P.M. (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 93, 232-239.
10. Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. & Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 325, 393-397.
11. Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., Bevan, D., Mackie, I. & Machin, S. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology, 142, 819-826.
12. Vesely, S.K., George, J.N., Lämmle, B., Studt, J.D., Alberio, L., El-Harake, M.A. & Raskob, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 60-68.
13. Veyradier, A., Obert, B., Houllier, A., Meyer, D. & Girma, J.P. (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood, 98, 1765-1772.
14. Wyllie, B.F., Garg, A.X., Macnab, J., Rock, G.A. & Clark, W.F. (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. British Journal of Haematology, 132, 204-209.
15. Zheng, X.L., Kaufman, R.M., Goodnough, L.T. & Sadler, J.E. (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 103, 4043-4049.